PRTG Stock Summary and Trading Ideas (Portage Biotech | NASDAQ:PRTG)

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech trades on the NASDAQ stock market under the symbol PRTG.

As of March 13, 2025, PRTG stock price declined to $4.04 with 25,109 million shares trading.

PRTG has a beta of 1.09, meaning it tends to be more sensitive to market movements. PRTG has a correlation of 0.01 to the broad based SPY ETF.

PRTG has a market cap of $6.65 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PRTG traded as high as $239.80 and as low as $2.10.

PRTG has underperformed the market in the last year with a price return of -65.7% while the SPY ETF gained +8.2%. However, in the short term, PRTG had mixed performance relative to the market. It has outperformed in the last 3 months, returning +34.7% vs -8.4% return in SPY. But in the last 2 weeks, PRTG shares have been beat by the market, returning -6.9% compared to an SPY return of -5.7%.

PRTG support price is $3.74 and resistance is $4.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTG shares will trade within this expected range on the day.